Novartis CML Oncology Scientific Exchange (OSE) – Treatment Free Remission in CML: Emerging Data and Considerations for Treatment Selection.
This Novartis CML OSE virtual event will focus on emerging data from longer-term follow-up in TFR clinical studies, the benefit/risk profiles of TKIs and key treatment considerations, and offer an engaging platform to discuss important advancements in the field with international experts from the medical community.